Company intelligence / Profile preview

YJ Biotech

Linkou District, New Taipei City, Taiwan

Ownership: Private
Development stage: Other

Overview

YJ Biotech has achieved significant certifications in cell manufacturing (GTP and ISO/IEC 17025) and developed a pharmaceutical-grade cell isolator. It produces high-quality stem cells and exosomes for other companies and clinical institutions, with notable progress in 2024 through regulatory and national innovation awards. Currently, the company supports mainly pre-clinical and academic clinical trial research involving cell therapies for degenerative disease and cancer.

Therapeutic areas: OncologyNeurology
Modalities: Cell therapyExosome-based therapyStem cell therapy
Industry: Contract Manufacturing Organization

Partnerships

Academic research institutions (unnamed)Pharmaceutical and biotech companies using stem cell and exosome manufacturing

Beyond the preview

Go deeper on YJ Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YJ Biotech.

Explore the full profile